Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ascenta Therapeutics
Further Study Details provided by Ascenta.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed Stage IIIb with pleural/pericardial effusion or Stage IV non-small cell lung cancer (NSCLC).
Progression of disease after one prior systemic chemotherapeutic regimen for locally advanced or metastatic NSCLC. (Systemic therapies given in the adjuvant setting are counted only if the patient relapses within 6 months of the last cycle of therapy.) In addition to the one prior chemotherapeutic regimen, patients may have received erlotinib in any setting.
All patients must have measurable disease.
No unstable or progressive brain metastases.
Patients may have received prior radiation therapy but they must have recovered from all treatment-related toxicities.
ECOG performance status 0-1
Adequate hematologic function
Adequate liver and renal function
Ability to swallow oral medication
You may not be if
Prior chemotherapy regimen containing docetaxel.
Active secondary malignancy.
Uncontrolled concurrent illness including, but not limited to: serious uncontrolled infection, symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
Failure to recover from toxicities related to prior therapy (e.g., surgery, radiation, chemotherapy).
Clareo Health | A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
